Does Ziopharm Oncology Inc (NASDAQ:ZIOP) Have Gas After Even Less Sellers Involved?

March 16, 2018 - By Clifton Ray

 Does Ziopharm Oncology Inc (NASDAQ:ZIOP) Have Gas After Even Less Sellers Involved?

The stock of Ziopharm Oncology Inc (NASDAQ:ZIOP) registered a decrease of 5.93% in short interest. ZIOP’s total short interest was 31.14 million shares in March as published by FINRA. Its down 5.93% from 33.10M shares, reported previously. With 2.47M shares average volume, it will take short sellers 13 days to cover their ZIOP’s short positions. The short interest to Ziopharm Oncology Inc’s float is 28.63%.

The stock increased 1.37% or $0.06 during the last trading session, reaching $4.43. About 476,066 shares traded. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 1.75% since March 16, 2017 and is uptrending. It has underperformed by 14.95% the S&P500.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company has market cap of $624.53 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma . It currently has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 9 analyst reports since December 4, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by Raymond James given on Thursday, June 2. The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) earned “Market Perform” rating by Wells Fargo on Wednesday, August 10. H.C. Wainwright maintained ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) on Monday, March 5 with “Buy” rating. H.C. Wainwright maintained the shares of ZIOP in report on Thursday, December 14 with “Buy” rating. The company was initiated on Friday, December 4 by Wells Fargo. The rating was maintained by Mizuho on Monday, January 25 with “Neutral”. The firm has “Neutral” rating given on Wednesday, May 11 by Mizuho.

More news for ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) were recently published by:, which released: “Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results …” on March 01, 2018.‘s article titled: “Technical Perspectives on Biotech Stocks — Vericel, Viking Therapeutics …” and published on March 14, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.